China Universal Asset Management Company’s Kiniksa Pharmaceuticals KNSA Stock Holding History

China Universal Asset Management Company’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Sell	7,369 -776	-10%	-$40.3K	0.03%	271
2026 Q1	$392K	Buy	8,145 +786	+11%	+$34.8K	0.03%	282
2025 Q4	$304K	Sell	7,359 -261	-3%	-$10.5K	0.02%	301
2025 Q3	$296K	Sell	7,620 -883	-10%	-$28.7K	0.02%	295
2025 Q2	$235K	Buy	8,503 +77	+0.9%	+$1.96K	0.02%	296
2025 Q1	$187K	Sell	8,426 -388	-4%	-$7.99K	0.02%	319
2024 Q4	$174K	Buy	8,814 +1,004	+13%	+$22.9K	0.02%	337
2024 Q3	$195K	Buy	7,810 +3,076	+65%	+$74.9K	0.02%	304
2024 Q2	$88.4K	Sell	4,734 -2,974	-39%	-$55.7K	0.01%	309
2024 Q1	$152K	Buy	7,708 +3,611	+88%	+$70.5K	0.02%	327
2023 Q4	$71.9K	Buy	4,097 +3,186	+350%	+$52.4K	0.01%	324
2023 Q3	$15.8K	Buy	911 +453	+99%	+$7.63K	﹤0.01%	314
2023 Q2	$6.45K	Sell	458 -10	-2%	-$134	﹤0.01%	345
2023 Q1	$5.04K	Buy	468 +117	+33%	+$1.54K	﹤0.01%	365
2022 Q4	$5.26K	Buy	351 +28	+9%	+$408	﹤0.01%	293
2022 Q3	$4K	Buy	+323	New	+$3.68K	﹤0.01%	301

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

China Universal Asset Management Company's KNSA Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Kiniksa Pharmaceuticals (KNSA) stake by 9.5% in Q2 2026, selling an estimated $40.3K and leaving 7,369 shares worth $471K. The position accounts for 0.03% of the portfolio, ranked #271.

China Universal Asset Management Company first reported a position in KNSA in Q3 2022 and has held it in 16 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

China Universal Asset Management Company held 7,369 shares of Kiniksa Pharmaceuticals worth $471K as of Q2 2026.
China Universal Asset Management Company sold 776 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $40.3K.
Kiniksa Pharmaceuticals made up 0.03% of China Universal Asset Management Company's portfolio in Q2 2026, its #271 holding.
China Universal Asset Management Company first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.